Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- panitumumab
- Photofrin (porfimer)
Interactions between your drugs
porfimer panitumumab
Applies to: Photofrin (porfimer), panitumumab
Using porfimer together with panitumumab may increase the risk of a photosensitivity reaction (e.G., redness, swelling, itching, burning sensation, feeling hot, and/or blisters), following exposure to sunlight or bright indoor lights such as examination, dental or operating room lamps; floodlights; halogen lights; and unshaded light bulbs at close proximity. It is recommended that panitumumab be avoided for at least 30 days following therapy with porfimer, and until a test for residual photosensitivity shows no photosensitivity reaction within 24 hours. In some cases, it might be necessary to avoid photosensitizing medications for 90 days or longer, although it may not be feasible to interrupt some treatments for that long, especially if they are medically necessary. Exposing your skin to normal indoor lighting is helpful as it will help your body get rid of porfimer more quickly, so you do not need to stay inside in the dark. Check with your doctor to see if you should temporarily withhold any of your medications after taking porfimer or if you have any other questions. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Betaseron
Betaseron is used to treat relapsing multiple sclerosis (MS). Learn about side effects ...
Leucovorin
Leucovorin is used for anemia, megaloblastic, colorectal cancer, folic acid antagonist overdose ...
Oxaliplatin
Oxaliplatin (Eloxatin) is a cytotoxic chemotherapy drug used to treat stage III colon cancer and ...
Nivolumab
Nivolumab is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Bevacizumab
Bevacizumab injection is a targeted cancer drug used to treat types of non-small cell lung cancer ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.